Fosun Pharma, a healthcare group in China, terminated the $158m acquisition of a 60% stake in OncoCare, a service provider of cancer treatment centers. Since the deal involved “a series of preliminary factors” that both parties could not fulfil before the due date on October 30, the two parties decided to terminate the transaction.